Hyperfine Enrolls 1,000+ Patients in Contrast MRI Study

Hyperfine Inc., based in Guilford, Connecticut, has concluded enrollment in a pivotal contrast-enhanced MRI study, marking a key milestone in its development of the Swoop portable MRI system. The trial, registered under ClinicalTrials.gov as NCT07296263, focuses on assessing the Swoop system’s ability to visualize brain lesions—particularly those associated with blood-brain barrier disruption—using ultra-low-field imaging with gadolinium-based contrast agents. The study targets conditions such as brain tumors and inflammatory disorders, with endpoints centered on lesion appearance across three key metrics.